Genetically engineered mice with mutations in TGFßs and FGF2 are being used by my laboratory. This has resulted in models for the following human diseases: autoimmune disease, colon cancer, congenital heart defects and cardiac hypertrophy. These models are providing a better understanding of these diseases and the roles that TGFß and FGF2 play in their development.
Tom Doetschman, PhD
Molecular Medicine Grad Program:
Samadder, P., N. Weng, T. Doetschman, R. L. Heimark, and D. W. Galbraith, "Flow cytometry and single nucleus sorting for Cre-based analysis of changes in transcriptional states.", Cytometry A, 2016 Mar 22. PMID: 27003621
Ardila, D. C., E. Tamimi, F. L. Danford, D. G. Haskett, R. S. Kellar, T. Doetschman, and J. P. Vande Geest, "TGFβ2 differentially modulates smooth muscle cell proliferation and migration in electrospun gelatin-fibrinogen constructs.", Biomaterials, vol. 37, pp. 164-73, 2015 Jan. PMCID: PMC4312204 PMID: 25453947
Sanford, L. P., I. Ormsby, A. C. Gittenbe de Groot, H. Sariola, R. Friedman, G. P. Boivin, E. L. Cardell, and T. Doetschman, "TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes.", Development, vol. 124, issue 13, pp. 2659-70, 1997 Jul. PMCID: PMC3850286 PMID: 9217007
Shull, M. M., I. Ormsby, A. B. Kier, S. Pawlowski, R. J. Diebold, M. Yin, R. Allen, C. Sidman, G. Proetzel, and D. Calvin, "Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease.", Nature, vol. 359, issue 6397, pp. 693-9, 1992 Oct 22. PMCID: PMC3889166 PMID: 1436033